Meda AB

Last updated
Meda AB
FoundedJune 6, 1991;33 years ago (1991-06-06)
Headquarters,
Sweden
Revenue SEK 15 billion (2014)
Number of employees
5,202 (2014)
Parent Viatris
Divisions MedPointe

Meda AB is a specialty pharmaceutical company, headquartered in Solna, Sweden. Meda imports and markets pharmaceuticals, nutritional, and health-care products, and offers services including clinical research, registration, and logistics. At the end of 2014, Meda had 5,202 employees. Meda's pharmaceuticals are currently sold in more than 150 countries. [1] [ self-published source ]

Meda was listed on the Stockholm Stock Exchange until it was acquired by Mylan in 2016 through a cash and stock offer valued €7.2 billion. [2]

Mergers, acquisitions and divestments

In 2005, Meda bought German pharmaceutical brand Viatris GMBH from Advent International for €750million ($926 million). [3]

On 20 July 2007, Meda announced an $800 million cash-and-stock deal to buy the New Jersey–based pharmaceutical company MedPointe from a group of U.S. investors. MedPointe bought the diagnostics and drug businesses of Carter-Wallace in 2001, with the consumer product line going to Church & Dwight. [4] The deal was completed on 22 August with Meda entering the US market. The new shareholders in Meda are The Carlyle Group, The Cypress Group LLC, and other US investors, who had a combined shareholding in Meda of approximately 7%. [5]

In 2014, Meda acquired the Italian firm Rottapharm Madaus in order to add consumer health products to their portfolio. [6] Meda explored in 2015 the possibility of divesting its United States division, Meda Pharmaceuticals, to raise funds for expansion in other areas. [6]

Related Research Articles

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Merck Group</span> German multinational science and technology company

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Geritol</span> Dietary supplement brand

Geritol is a United States trademarked name for various dietary supplements, past and present. Geritol is a brand name for several vitamin complexes plus iron or multimineral products in both liquid form and tablets, containing from 9.5 to 18 mg of iron per daily dose. The name conveys a connection with aging, as in "geriatric". The product has been promoted from almost the beginning of the mass media era as a cure for "iron-poor tired blood".

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

<span class="mw-page-title-main">King Pharmaceuticals</span> American pharmaceutical company

King Pharmaceuticals, Inc. is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

Galderma S.A. is a Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé, it has been held by a consortium of private institutional investors since 2019.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

Avista Capital Partners is an American private equity firm headquartered in New York City focused on growth capital and leveraged buyout investments in middle-market companies in the domestic healthcare sector.

<span class="mw-page-title-main">Dechra Pharmaceuticals</span> Pharmaceutical Company based in UK

Dechra Pharmaceuticals plc is a business involved in the development and marketing of veterinary products based in Northwich, England. It is listed on the London Stock Exchange until it was acquired by EQT AB in January 2024.

<span class="mw-page-title-main">Recipharm</span> Swedish pharmaceutical manufacturer

Recipharm AB is one of the five largest pharmaceutical contract development and manufacturing organizations in the world, with production facilities in Sweden, France, Germany, Italy, Spain, Portugal, India and the UK as well as development sites in Sweden, Israel and the United States. The Swedish-based company employs around 5,200 people and operates over 18 facilities. The company provides pharmaceutical companies around the world with end-to-end development and manufacturing services, including a wide variety of dosage forms. Recipharm was listed on the Stockholm Stock Exchange in April 2014.

Carter-Wallace was a personal care company headquartered in New York City. The company was formed by the merger of Carter Products and Wallace Laboratories. The company had a research facility in Cranbury, New Jersey.

<span class="mw-page-title-main">Enli Health Intelligence</span>

Enli Health Intelligence was a privately held software company based in Beaverton, Oregon, and previously in Hillsboro, Oregon. Founded in 2001 as Kryptiq Corporation, the company specialized in electronic medical records and secure communications between physicians and patients. The 125-employee company was purchased by Surescripts in 2012, which was a previous investor in the company. Annual revenues at the time of the sale were approximately $25 million. In January 2015, the company announced that it was splitting from Surescripts and becoming independent again. Later in 2015, it was renamed Enli Health Intelligence. In 2021, it was acquired by Cedar Gate Technologies, which discontinued use of the Enli name.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

References

  1. "About Meda". Meda AB. Retrieved 15 August 2015.
  2. "Mylan compra Meda, affare da $7,2 miliardi". www.pharmastar.it. Retrieved 15 July 2021.
  3. https://invivo.citeline.com/deals/200510151
  4. "Meda to Buy MedPointe for $800 Million in Cash, Stock". CNBC . 20 July 2007.
  5. "Strategic acquisition of MedPointe Inc completed" (Press release). 22 August 2007.
  6. 1 2 Ewing, Adam; Baigorri, Manuel (27 August 2015). "Swedish Drugmaker Meda Said to Weigh Sale of U.S. Operations". Bloomberg Business. Retrieved 28 August 2015.